鹰瞳科技-B2024年年度报告

Beijing Airdoc Technology Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability)Stock Code: 2251 2024ANNUALREPORT CONTENTS Corporate Information2Financial Summary5Chairman’s Statement6Management Discussion and Analysis11Profiles of Directors, Supervisors andSenior Management49Corporate Governance Report58Environmental, Social and Governance Report90Report of the Directors170Report of the Supervisors219Independent Auditor’s Report222Consolidated Statement of Profit or Loss233Consolidated Statement of Comprehensive Income234Consolidated Statement of Financial Position235Consolidated Statement of Changes in Equity237Consolidated Statement of Cash Flows239Notes to the Consolidated Financial Statements243Definitions and Glossary of Technical Terms396 CORPORATE INFORMATION BOARD OF DIRECTORS Executive Directors Mr. ZHANG Dalei(Chairman and chief executive officer)Ms. WANG LinDr. HE ChaoMr. QIN Yong Independent Non-executive Directors 202410 1820248 28 Dr. WU YangfengDr. HUANG YanlinMr. NG Ho Yin Owen(appointed on October 18, 2024)Mr. NG Kong Ping Albert(resigned on August 28, 2024) SUPERVISORS Mr. WEI YuboMs. BAI HuihuiDr. LUO Ting AUDIT COMMITTEE 202410 1820248 28 Mr. NG Ho Yin Owen(Chairman, effective from October 18, 2024)Mr. NG Kong Ping Albert(Chairman, resigned on August 28, 2024)Dr. HUANG YanlinDr. WU Yangfeng REMUNERATION AND APPRAISALCOMMITTEE 202410 1820248 28 Dr. HUANG Yanlin(Chairman)Ms. WANG LinMr. NG Ho Yin Owen(effective from October 18, 2024)Mr. NG Kong Ping Albert(resigned on August 28, 2024) NOMINATION COMMITTEE Mr. ZHANG Dalei(Chairman)Dr. HUANG YanlinDr. WU Yangfeng 2024北京鷹瞳科技發展股份有限公司CORPORATE INFORMATION STRATEGY COMMITTEE 202410 1820248 28 Mr. ZHANG Dalei(Chairman)Dr. WU YangfengMr. NG Ho Yin Owen(effective from October 18, 2024)Mr. NG Kong Ping Albert(resigned on August 28, 2024) ESG COMMITTEE Mr. ZHANG Dalei(Chairman)Ms. WANG LinDr. HE Chao AUTHORIZED REPRESENTATIVES Mr. ZHANG DaleiMs. SO Lai Shan JOINT COMPANY SECRETARIES 20251 2020251 20 Ms. WANG Xinfeng(effective from January 20, 2025)Ms. SO Lai Shan(ACG (CS, CGP) HKACG (CS, CGP))Ms. YANG Wenting(cease on January 20, 2025) HEAD OFFICE, REGISTERED OFFICE ANDPRINCIPAL PLACE OF BUSINESS IN THEPRC 22421 Room 21, 4th Floor, Building 2, A2 YardWest Third Ring North RoadHaidian DistrictBeijingPRC PRINCIPAL PLACE OF BUSINESS INHONG KONG 33191901 Room 1901, 19/F, Lee Garden One33 Hysan AvenueCauseway BayHong Kong H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong HONG KONG LEGAL ADVISER 1526 Kirkland & Ellis26/F, Gloucester TowerThe Landmark15 Queen’s Road CentralHong Kong PRC LEGAL ADVISER 2022–31 Zhong Lun Law Firm22–31/F, South Tower of CP Center20 Jin He East AvenueChaoyang DistrictBeijingPRC AUDITOR 97927 Ernst & Young Certified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry BayHong Kong STOCK CODE 2251 2251 COMPANY WEBSITE www.airdoc.com www.airdoc.com FINANCIAL SUMMARY財務概要 A summary of the results and of the assets and liabilities ofthe Group for the last five financial years, as extracted fromthe audited financial information and financial statements isset out below: CHAIRMAN’S STATEMENT Dear Shareholders 20241231Airdoc I am pleased to present our annual report for the year ended31 December 2024. On behalf of the Board and Airdoc, wewould like to express our sincere gratitude for yourcontinuous support and trust over the years. 2024 In the challenging and transformative year of 2024, Airdocremained steadfast in its commitment to a “customer-first”philosophy, to confront the complex and volatile externalenvironment with a sense of reverence. This year, theadjustment of industry policies and shifts in the marketenvironment brought unprecedented challenges to thedevelopment of enterprises, preventing us from maintainingthe rapid growth trajectory of previous years. Nevertheless,the Company will continue to strengthen its technologicalfoundation, optimize operational efficiency, and expandapplication scenarios to solidify the groundwork for long-term development. AIAI2024AIAIAI Airdoc, a leader in AI retina analysis and a pioneer innon-invasive light therapy for myopia, is dedicated toproviding comprehensive, multi-dimensional, and integratedAI solutions for the auxiliary diagnosis of chronic diseases,health risk assessment, and myopia management. In 2024,w h i l ew e c o n t i n u e d t o m a i n t a i n t h e e x c e p t i o n a lcompetitiveness of our existing algorithm platforms, wemade significant progress in the research and developmentof Large Language Models, and successfully filed a nationaldeep synthesis service algorithm. In addition, we have beenactively expanding our product lines, establishing anintegrated intelligent medical product matrix centeredaround the “Wanyu Large Language Model ()”. This m